scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Bought by King Luther Capital Management Corp

King Luther Capital Management Corp grew its holdings in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 51.8% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,205,140 shares of the company’s stock after purchasing an additional 752,005 shares during the quarter. King Luther Capital Management Corp owned approximately 6.12% of scPharmaceuticals worth $9,592,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SCPH. AIGH Capital Management LLC boosted its holdings in scPharmaceuticals by 40.8% in the fourth quarter. AIGH Capital Management LLC now owns 3,106,795 shares of the company’s stock valued at $19,480,000 after purchasing an additional 899,786 shares during the last quarter. IPG Investment Advisors LLC acquired a new position in scPharmaceuticals in the fourth quarter valued at approximately $75,000. Rubric Capital Management LP boosted its position in scPharmaceuticals by 29.0% during the 4th quarter. Rubric Capital Management LP now owns 3,500,000 shares of the company’s stock valued at $21,945,000 after purchasing an additional 786,713 shares during the period. Thomasville National Bank lifted its stake in scPharmaceuticals by 11.5% in the first quarter. Thomasville National Bank now owns 36,800 shares of the company’s stock valued at $185,000 after buying an additional 3,800 shares during the last quarter. Finally, Perkins Capital Management Inc. bought a new stake in scPharmaceuticals in the first quarter valued at $53,000. Institutional investors and hedge funds own 89.52% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of scPharmaceuticals in a research note on Monday, August 19th.

scPharmaceuticals Stock Down 1.5 %

Shares of scPharmaceuticals stock opened at $5.18 on Friday. scPharmaceuticals Inc. has a 1-year low of $3.24 and a 1-year high of $7.37. The company has a market capitalization of $259.16 million, a P/E ratio of -3.50 and a beta of 0.13. The business’s fifty day moving average price is $4.96 and its two-hundred day moving average price is $4.70. The company has a debt-to-equity ratio of 4.32, a current ratio of 4.84 and a quick ratio of 3.66.

scPharmaceuticals (NASDAQ:SCPH) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.44) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.44). The business had revenue of $8.05 million for the quarter, compared to analysts’ expectations of $8.04 million. scPharmaceuticals had a negative net margin of 252.18% and a negative return on equity of 201.84%. As a group, research analysts forecast that scPharmaceuticals Inc. will post -1.34 EPS for the current year.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.